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Introduction
In this article, I focus on processes of scientific self-governance and standardization in the context of intercontinental clinical research collaborations in the field of regenerative stem cell medicine. I will explore, furthermore, the implications of these processes on local clinical innovation practices, and the production of localized forms of economic value. The paper explores these issues by focusing on the formation of the China Spinal Cord Injury Network (China SCI Net), the first intercontinental clinical trials infrastructure in the stem cell field that has emerged between medical researchers in mainland China, Hong Kong, Taiwan and the USA.
The emergence of a global clinical trial landscape has been a key theme in the literature on industry-sponsored forms of clinical research on vaccines and drugs based on chemical compounds (Leach et al., 1999; Gikonyo, Bejon, Marsh, & Molyneux, 2008; Petryna 2009; Sariola, & Simpson, 2011) . To date, however, no study has systematically focused on the formation of international clinical trials in the field of regenerative stem cell medicine. Existing academic work on the clinical translation of stem cell-based therapeutic approaches has focused either on processes of preclinical development (Cribb, et al., 2008; Martin, Brown and Kraft, 2008;  M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 2011; Chen, & Gottweis, 2011; Rosemann, 2013a) and India (Bharadwaj, 2013; Sleeboom-Faulkner, & Patra 2011) .
The development of regenerative stem cell medicine through internationally acknowledged multi-country clinical trial partnerships has remained unexplored so far. This is an important analytical shortcoming. A focus on the formation of international clinical trial infrastructures provides important opportunities to gain insights into the processes and challenges involved in the development, organization, and governance of large-scale, transcontinental clinical research collaborations in the field of regenerative stem cell medicine (as well as other emerging fields of medicine research). Of particular interest, in this respect, are processes of standardization, which in recent years have evolved as important concerns in the social study of medicine research (Timmermans, & Berg, 1997; Timmermans, & Epstein, 2010; Birch, 2012) . The evolving field of clinical stem cell medicine forms an interesting case in this respect. In contrast to established forms of drug research, for clinical stem cell research there are as yet no internationally binding standards or harmonized global governance frameworks, and widely divergent regulatory conditions exist across (and within) countries. The governments of the USA, the European Union and some other countries have now developed legal arrangements for the licensing of stem cell-based medicinal products (Halme, & Kessler, 2006; Faulkner, 2012) . In many other countries, however, including in population rich countries such as China and India -where unproven for-profit applications with stem cells constitute a huge market -the development of regulatory frameworks is evolving only gradually (Sleeboom-Faulkner, & Patra, 2011; Rosemann, 2013a) . In China, the experimental clinical use of stem cells remained completely unregulated until January 2012, with the result that highly dissimilar types of clinical research and experimental for-profit M A N U S C R I P T
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6 applications have surfaced since the early 2000s (Chen, 2009; Song, 2011; Rosemann, 2013a) .
The argument in this paper is developed in two parts. First, I will show that the high level of regulatory diversity in the international landscape of clinical stem cell research, poses a significant challenge to the organization of cross-continental clinical trial collaborations. By focusing on the formation of the China Spinal Cord Injury Network (China SCI Net), the first trans-continental clinical trial infrastructure in stem cell medicine between China and the USA, the article will elucidate that the enactment of internationally recognized clinical research standards is a complex and highly situation-specific achievement. Standardization, as will be shown, relies on extensive forms of scientific self-governance, and requires far-reaching adjustments of local clinical research environments. Internationally approved methodological protocols are established against a background of regulatory, institutional and epistemic-cultural heterogeneity, and implemented in the situational context of the clinical trials organized by the China SCI Net. Exterior to the activities of the China SCI Net, we see that locally evolved and newly adopted (i.e. internationally accepted) forms of experimental clinical research practices exist side by side with each other, often in the same medical institutions. Researchers shift between these divergent schemas, depending on the purposes of their research, the partners they work with, the geographic scale of research projects, and the contrasting demands for regulatory review, that result from these differences. Second, based on these insights I will engage in a dialogue with a recent analysis of the role of standardization in the creation of value in the biosciences by sociologist Kean Birch (2012) . I will argue that -in the regenerative medicine field -the integration of local knowledge institutions into the global bioeconomy does not necessarily result in the shutting down of M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 7 localized forms of value production. While the blocking of local forms of capital production in the biomedical sciences can be observed in particular in established fields of medical research, and in countries with stringent regulatory controls in place, in emerging fields of medicine research, a more diversified situation exists. In emerging socio-technical fields of medical research, such as regenerative stem cell medicine, which is regulated in highly divergent ways across (and often within) geographical regions, the close proximity between locally evolved and internationally recognized forms of clinical translation allows also for the production of multiple forms of economic and scientific value. Localized forms of value creation in medical institutions, that do not conform to the requirements of international scientific standard regimens, continue to exist -aside to participation in internationally approved, multi-country clinical research projects. Geographic location, and regulatory differences between these locations, is a key factor in explaining this situation. As this paper shows, the long-standing absence of a comprehensive regulatory framework for clinical stem cell applications in China permits the situation-specific adoption of internationally recognized standards in some contexts, while enabling the continuation of local forms of value production in others. (Rosemann, 2013b) . Since 2009, the China SCI Net has been paralleled by the Spinal Cord Injury Network USA (SCI Net USA), which comprises eight academic hospitals. The aim of this evolving transnational research economy is to develop and clinically assess stem cell-based combination therapies for spinal cord injury, and the licensing of successfully tested treatments in China, Hong Kong, Taiwan, the USA, and potentially other countries in the world. Until April 2014, the China SCI Net had conducted seven clinical studies. An initial noninterventional observational study was carried out between 2005 and 2008 in twenty-two hospitals to collect diagnostic and long-term follow-up data from up to 600 acute and chronic SCI patients. This study was followed by five phase I and II trials that have been conducted in chronic SCI patients, in two university hospitals in Hong Kong and one military hospital in China. Two of these studies tested the safety and efficacy of lithium in SCI patients, and three studies an experimental combination therapy of umbilical cord blood (UCB) mononuclear cells, lithium, and methylprednisolone. A Phase III trial incorporating more hospitals (including those in Taiwan) is being planned in 2014. The SCI Net USA has not yet conducted clinical trials, but Phase II and Phase III studies are in preparation. The UCB stem cells that are used in the trials of the Network are sponsored by the US-Taiwanese umbilical cord blood bank company Stemcyte. The organization of the trials itself is covered by financial resources raised within China and Hong Kong (Rosemann, 2013b) . analyzed against the wider background of clinical stem cell research and applications in these regions, particularly in mainland China (Rosemann, 2011 (Rosemann, , 2013a . The data generated in Taiwan are not included in this article because the main activities of the Network during the fieldwork stage took place in Hong Kong and China.
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Several methods of data collection were employed during the research process. Open-ended, in-depth interviews were conducted with twenty-eight people affiliated to the China SCI Net. These included senior executives, principal investigators, clinical researchers, and fundraisers, from ten participating hospitals and institutes. These interviews were either tape-recorded and transcribed verbatim, or recorded by hand during the interview process. All interviewees were explained the purposes of the research, and verbal consent to use interview data for academic publications was obtained. Documentary research was conducted using text sources provided by people from the Network and from the Internet. These documentary sources included scientific papers, opinion pieces, newspaper articles, blog contributions of researchers, as well as video-documentation of panel discussions and presentations during international symposia organized by the China SCI Net. The article draws, furthermore, on observations of scientific conferences, expert meetings, and visits to hospitals and research centers. The research that underlies this article has received ethical review and approval by the University of Sussex.
Data analysis was ongoing during fieldwork and in the months thereafter.
Everyday work practices and organizational procedures were examined in relation to the institutional and regulatory orders, in whose context these activities took place (Smith 2005) . By repeatedly reading and coding interview transcripts, field notes and relevant text sources I identified, in a first step, the different stages and procedures through which standardized research protocols were developed and implemented in M A N U S C R I P T
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10 the context of the China SCI Net. Then, in a second step I explored the challenges to standardization, and the ways in which these difficulties were interpreted and tried to be solved. This second line of analysis was based on the constant comparative method (Boeije 2002 ) and triangulation of data from different sources. In a third step I examined the similarities and differences between locally evolved and internationallyrecognized experimental clinical practices in hospitals that take part in international stem cell trials. In order to discern the specific forms of value creation that emerged from these distinct experimental practices, I relied on the investigation of interview data and the analysis of hospital websites, commonentary and opinion pieces, as well as advertising materials from the Internet.
Intercontinental stem cell trials and the role of scientific self-governance
What we are trying to do is to bring the international standards of clinical trials to and people is based on an interconnected sequence of organizational procedures, educational, and training activities, and the employment of a tailor-made monitoring and control system. In the absence of a harmonized global governance framework for clinical stem cell research, these efforts rest primarily on extensive forms of transnational scientific self-governance. Such project-internal forms of selfgovernance are strategic efforts to navigate through a diverse and internationally nonharmonized regulatory environment; the aim is to create compliance with the divergent requirements of drug regulatory authorities and related processes of peer review in multiple countries (cf. Wahlberg, et al., 2013) . A focus on these processes of scientific self-governance, provides important insights into the ways in which scientists try to balance out regulatory disparities between regions and institutions, compensating for regulatory gaps, and creating congruence with the auditing demands of diverging regulatory and political systems (Sariola, & Simpson, 2011; SleeboomFaulkner, 2013) . When we first came here, the neurological assessment of spinal cord injuryalmost everywhere -was completely haphazard. It ranged from, eh, you know … you take a pin, you put it here, you touch a patient, ask "Can you feel it?"
There was no discipline … no common languages, no common neurological assessment of the patients. A crucial endeavor in this respect was the organization of the observational (i.e., non-interventional) trial CN100, a multicenter study that was conducted in twenty-two hospitals in mainland China, Hong Kong, and Taiwan. The purpose of this study was to collect long-term data from 600 chronic and acute spinal cord injury patients, in accordance with international recruitment and measurement protocols. In addition to the scientific value of this studywhich was the first longitudinal observational study of chronic and acute spinal cord injury patients in Chinait fulfilled a central function for the Network: to serve as a test trial of the ability of affiliated centers to recruit patients, to conduct standardized neurological assessments
[based on the ASIA scheme, developed by the ISCS], to carry out long-term followups, and to document data and data-collection procedures in the prescribedstandardizedfashion. This study helped in identifying various challenges:
The first trial we held was an observational trial. To show that the hospitals can deliver the data … Now this study revealed a lot of problems I actually had heard about, but never really encountered, until to this point. The number one problem in China is really to get patients to come back [for follow-up investigations]. … But we [also] observed data that just could not have been.
You know -patient data would be the same, over the whole year period.
Suggesting that someone had examined the patients very carefully … It became very clear to us that we need to have very good controls of the protocol. In the China SCI Net we see processes of collectivization and standardization emerging that in several respects are similar to the cooperative clinical trial system described by Keating and Cambrosio. In the mid-2000s, at the time the China SCI Net was launched, the organization of an academia-based multicenter clinical trial infrastructure was still a radical novelty in the stem cell field in China. While standardized multicenter drug trials had been conducted in China by multinational pharmaceutical companies since the early 1990s (Cooper, 2006) , clinical M A N U S C R I P T
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19 experimentations with stem cells were for many years based largely on an "the-art-ofmedicine" approach, in which tailor-made experimental treatments were designed for the idiosyncratic needs and disease conditions of individual patients (Rosemann, 2013a) . Against this background, the formation of an internationally operating multicenter clinical trial infrastructure that would allow for the testing and marketization of stem cell-based medicinal products, not only in mainland China, but also in Hong Kong, Taiwan, and at a later point in the USA, was a radical and fundamentally new concept.
Similar to the cooperative oncology research groups described by Keating and pilot studies with stem cells were conducted, but none of these studies could be published in international journals because the methodology of these studies was described as insufficient (Young, 2008) . In a clinic in South China, on the other hand, depending on the purposes of their research, the partners they work with, the geographic scale of research projects, the targeted territorial scope of marketization, and the contrasting demands for regulatory review and approval that result from these differences. This situation differs fundamentally from the oncology research cooperatives described by Keating and Cambrosio (2011) , where the adoption of a centrally defined set of research standards has become a permanent and obligatory requirement, and possibilities for clinical experimentation outside of the cooperative structure have become impossible.
The continuance of localized forms of value production
A key point is that the coexistence of distinct modes of clinical translation allows also for the production of multiple forms of economic value, at the level of local medical institutions. Localized forms of value creation, which would not be acceptable to drug China (Chen, 2009; Song, 2011) , as well as India (Sleeboom-Faulkner, & Patra 2011).
As recently suggested by McMahon (2014) , the provision of unproven stem cell intervention has itself developed into a global industry that is now provided to tens of thousands of patients and generate significant economic revenues.
Here, two issues deserve to be mentioned. The first is that participation of hospitals in international clinical research projects may increase the level of legitimacy for the provision of locally evolved experimental therapies. This, in turn, is likely to maximize local forms of value creation, also if these treatments have not been developed in accordance with internationally recognized clinical research standards. The second point is that the integration of hospitals into a multi-country M A N U S C R I P T
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27 clinical trial infrastructure may foster the adoption of an evidence-based medicine (EBM) research culture -also in the context of local research projects. In the case of the China SCI Net, for example, several of the investigators with whom I spoke had started to conduct randomized controlled trials, including domestic multi-center studies, independently from the China SCI Net. These researchers reported that, in the field of spinal cord injury research, the shift toward more systematic clinical trials was driven in particular by discontent with the widespread availability of unproven for-profit stem cell therapies in China, and related concerns for patients.
Local value and the violation of property rights
A point that is thematically related to the argument of this article, albeit not central to it, is that possibilities for the continuation of localized forms of value creation are also linked to cross-national differences in the enforcement of intellectual property rights (IPR). In India, China and other rapidly developing countries the protection and enforcement of property rights is often problematic. In China and India, for example, a longstanding record of IPR infringements exists, including in the production of medicines (Brhlikova, et al., 2011; Mackay, & Liang, 2011) . IPR infringements are also an issue in the field of regenerative stem cell medicine. For instance, the umbilical cord blood mononuclear cell / Lithium combination that is tested by the China SCI Net (and which has been patented by Stemcyte, the sponsor of the UCB cells) was experimentally applied by a clinical researcher in India even before the initial Phase I trial of the China SCI Net in Hong Kong had started, apparently without any legal consequences. xi Similar forms of IPR infringements were also expected in China, provided the tested treatment is proved to be safe and efficient. 
